Junji Ueda1, Hiroshi Makino1, Tadashi Yokoyama1, Hiroshi Maruyama1, Atsushi Hirakata1, Hideyuki Takata1, Natsuki Seki1, Yuta Kikuchi1, Takuma Iwai1, Masafumi Yoshioka1, Mikihiro Okusa1, Manpei Kawashima1, Toshiyuki Irie1, Atsushi Inukai1, Mikito Suzuki1, Takahiro Haruna1, Hiroshi Yoshida2. 1Nippon Medical School Tamanagayama Hosipital, 2Nippon Medical School
Introdruction: Laparoscopic hepatectomy has spread worldwide with the development of various medical devices. We analyzed the use of laparoscopic hepatectomy for hepatocellular carcinoma at our institution.
Materials and Procedures: We analyzed 104 patients who underwent surgery for hepatocellular carcinoma from 2010 to 2018 at our institution. We divided these patients into two groups: the open hepatectomy group (OH) and the laparoscopic hepatectomy group (LH). We evaluated the clinicopathological findings, overall survival, and recurrence-free survival. In the LH group, there were more early-stage patients than in the OH group. We further analyzed the two groups by limiting groups to patients with Stage I and II cancer.
Results: In our study, 27 patients underwent laparoscopic hepatectomy (23.1%). The operation time, intraoperative bleeding, duration of hospital stay after surgery, and tumor diameter were significantly less in the LH group. Between the two groups, mortality rate, morbidity rate, overall survival rate, and recurrence-free rate did not significantly differ. We limited the patients to those in stages I and II. There were 56 patients in stages I and II, and 23 patients were in the LH group. Intraoperative bleeding, duration of hospital stay after surgery, tumor diameter, and morbidity rate were significantly less in the LH group. Between the two groups, mortality rate, overall survival rate, and recurrence-free rate did not significantly differ.
Conclusions: Laparoscopic hepatectomy is a safe and feasible surgical method that results in less intraoperative bleeding and shorter hospital stay than open hepatectomy for both advanced and early-stage hepatocellular carcinoma.
Presented at the SAGES 2017 Annual Meeting in Houston, TX.
Abstract ID: 93442
Program Number: P639
Presentation Session: Poster Session (Non CME)
Presentation Type: Poster
sages_adbutler_leaderboard